导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 7.93% | 849/4773 |
| 近一周 | -2.61% | 2671/5462 |
| 近一月 | -3.86% | 2029/5421 |
| 近一季 | -3.68% | 1448/5209 |
| 近半年 | -2.85% | 2052/4920 |
| 近一年 | 10.79% | 961/4366 |
| 近两年 | 68.49% | 1005/2954 |
| 近三年 | 38.10% | 773/2253 |
| 成立以来 | 37.78% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
3.23% 777/4961 |
13.86% 1926/5312 |
- - |
- - |
| 2025 | 23.93% 1829/4813 |
2.52% 1349/3635 |
1.78% 2142/4076 |
18.65% 2265/4524 |
0.10% 2216/4813 |
| 2024 | 7.13% 1690/3463 |
-1.10% 1179/2808 |
-4.91% 1588/3014 |
14.25% 2021/3129 |
-0.29% 1370/3463 |
| 2023 | -2.85% 610/2656 |
9.02% 431/2280 |
-4.29% 1129/2385 |
-3.77% 985/2515 |
-3.24% 636/2655 |
| 2022 | -20.11% 936/2207 |
-10.87% 439/1919 |
0.43% 1549/2016 |
-12.39% 700/2113 |
1.86% 1111/2208 |
| 2021 | 29.46% 73/1822 |
4.22% 157/1255 |
16.20% 207/1330 |
4.39% 357/1466 |
2.41% 600/1822 |
| 2020 | - - |
- - |
- - |
- - |
-0.26% 1068/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 上银中证500指数增强型A VS. 长安沪深300非周期A(740101) |